# Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

> **NCT05374590** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **argenx** · enrollment: 12 (estimated)

## Conditions studied

- Generalized Myasthenia Gravis
- gMG

## Interventions

- **BIOLOGICAL:** Efgartigimod IV or Efgartigimod PH20 SC

## Key facts

- **NCT ID:** NCT05374590
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-08-18
- **Primary completion:** 2029-09
- **Final completion:** 2029-09
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05374590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05374590, "Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05374590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*